Recent updates from Galectin Therapeutics highlight positive regulatory feedback from the U.S. Food and Drug Administration regarding key elements for a planned Phase 3 registrational trial of belapectin in MASH cirrhosis patients. Additionally, the company significantly strengthened its balance sheet by successfully converting over one hundred million dollars of outstanding debt and accrued interest into equity through an agreement with its chairman, eliminating long-term debt liabilities.